Jin Medical International Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on March 17, 2026, covers the month of March 2026. The filing details the effective implementation of a 1-for-20 share consolidation and a share class reclassification for Jin Medical International Ltd., a Cayman Islands exempted company with principal executive offices in Changzhou, China.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions regarding share capital structure.
Material Changes
- Share Consolidation: Effective March 16, 2026, at 09:00 a.m. Eastern Time, the Company executed a 1-for-20 combination of all authorized and issued Class A and Class B ordinary shares.
- Share Count Reduction: Issued and outstanding Class A ordinary shares were reduced from 136,547,100 to 6,827,355. Issued and outstanding Class B ordinary shares were reduced from 20,000,000 to 1,000,000.
- Capital Structure: Authorized share capital is now US$50,000, divided into 45,000,000 Class A shares and 5,000,000 Class B shares, each with a par value of US$0.001.
- Trading Details: Class A shares continue to trade on Nasdaq under the symbol "ZJYL" on a consolidation-adjusted basis. The new CUSIP number is G5140V120.
Outlook, Management Commentary, and Risks
Management states the share consolidation is a proactive measure within the Company's strategic plan to maintain compliance with Nasdaq continued listing requirements, specifically triggered when the closing market price falls below US$1.00. The action is also intended to strengthen the long-term capital structure. The Board was previously authorized by shareholders at an Extraordinary General Meeting on January 30, 2026, to determine the timing and execution of such consolidations.
Investor Verification Checklist
- Verify the new CUSIP number (G5140V120) for Class A shares in brokerage accounts.
- Confirm the adjusted share count and par value in the Company's latest capitalization table.
- Monitor the stock price relative to the US$1.00 threshold to assess the risk of future consolidations, as the Board retains discretion to effect up to three consolidations within two years of the January 2026 EGM.
- Review the attached press release (Exhibit 99.1) for additional details on the strategic initiative.